Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Science translational medicine, 2016•science.org
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response
targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism
of action by PARP “trapping” and what this means for both clinical monotherapy and
combination with chemotherapeutic agents.
targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism
of action by PARP “trapping” and what this means for both clinical monotherapy and
combination with chemotherapeutic agents.
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
AAAS